Format

Send to

Choose Destination
Breast Cancer. 2007;14(2):132-49.

Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.

Author information

1
Division of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan. khatake@jfcr.or.jp

Abstract

Here we reviewed the recent progress of molecular targeting drugs, including trastuzumab, lapatinib, erlotinib and bevacituzumab. Fortunately, Her-2 positive cases of metastatic or relapsed cases, those with the worse prognosis, are responsive to trastuzumab-based chemotherapy. Lapatinib will likely be effective against trastuzumab-resistant cases and brain metastases. Furthermore, the introduction of bevacituzumab will improve VEGF-VEGFR- associated tumor growth.

PMID:
17485898
DOI:
10.2325/jbcs.977
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Loading ...
Support Center